In addition, lj‐2‐66 suppressed the proliferation of BRAF inhibitor‐resistant (BRAFi‐resistant) melanoma cells independent of their resistance status, suggesting that lj‐2‐66 may be a potential drug for BRAF‐mutant melanoma treatment. This evidence concerns the gene BRAF and melanoma.